ES2158360T3 - Mimeticos de rotacion en sentido inverso y metodos relacionados con ellos. - Google Patents

Mimeticos de rotacion en sentido inverso y metodos relacionados con ellos.

Info

Publication number
ES2158360T3
ES2158360T3 ES96937733T ES96937733T ES2158360T3 ES 2158360 T3 ES2158360 T3 ES 2158360T3 ES 96937733 T ES96937733 T ES 96937733T ES 96937733 T ES96937733 T ES 96937733T ES 2158360 T3 ES2158360 T3 ES 2158360T3
Authority
ES
Spain
Prior art keywords
reverse
mimetics
rotation
methods related
reverse sense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96937733T
Other languages
English (en)
Inventor
Michael Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecumetics Ltd
Original Assignee
Molecumetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecumetics Ltd filed Critical Molecumetics Ltd
Application granted granted Critical
Publication of ES2158360T3 publication Critical patent/ES2158360T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Toys (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS CONSTREÑIDOS CONFORMACIONALMENTE DE FORMULA (I), QUE MIMETIZAN LA ESTRUCTURA SECUNDARIA DE REGIONES DE ROTACION INVERSA DE PEPTIDOS Y PROTEINAS BIOLOGICAMENTE ACTIVOS. DICHAS SUSTANCIAS MIMETICAS DE ROTACION INVERSA SON UTILES EN UNA AMPLIA VARIEDAD DE CAMPOS, INCLUYENDO SU UTILIZACION COMO AGENTES TERAPEUTICOS Y DE DIAGNOSTICO. SE DESCRIBEN ASIMISMO BIBLIOTECAS QUE CONTIENEN DICHAS SUSTANCIAS MIMETICAS, ASI COMO METODOS DE SELECCION DE LAS MISMAS PARA IDENTIFICAR SUSTANCIAS BIOLOGICAMENTE ACTIVAS.
ES96937733T 1995-10-27 1996-10-24 Mimeticos de rotacion en sentido inverso y metodos relacionados con ellos. Expired - Lifetime ES2158360T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/549,007 US5929237A (en) 1995-10-27 1995-10-27 Reverse-turn mimetics and methods relating thereto

Publications (1)

Publication Number Publication Date
ES2158360T3 true ES2158360T3 (es) 2001-09-01

Family

ID=24191284

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96937733T Expired - Lifetime ES2158360T3 (es) 1995-10-27 1996-10-24 Mimeticos de rotacion en sentido inverso y metodos relacionados con ellos.

Country Status (10)

Country Link
US (1) US5929237A (es)
EP (1) EP0876371B1 (es)
JP (1) JPH11513986A (es)
KR (1) KR19990067102A (es)
AT (1) ATE203025T1 (es)
AU (1) AU719620B2 (es)
CA (1) CA2235138C (es)
DE (1) DE69613861T2 (es)
ES (1) ES2158360T3 (es)
WO (1) WO1997015577A1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
AU749305B2 (en) * 1997-09-19 2002-06-20 Serex, Inc. Methods to improve immunogenicity of antigens and specificity of antibodies
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
PE20010955A1 (es) * 1999-12-21 2001-10-11 Procter & Gamble Compuestos mimeticos de peptidos de giros beta y procesos para su fabricacion
US6872825B2 (en) 1999-12-21 2005-03-29 The Procter & Gamble Company Peptide β-turn mimetic compounds and processes for making them
AU2002250293B2 (en) 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
US8163289B2 (en) * 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
US7662960B2 (en) * 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
US7008941B2 (en) * 2001-05-16 2006-03-07 Myriad Genetics, Inc. Reverse-turn mimetics and methods relating thereto
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
US6943157B2 (en) * 2001-10-09 2005-09-13 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ES2310215T3 (es) * 2001-10-12 2009-01-01 Choongwae Pharma Corporation Estructuras mimeticas de giro inverso y metodo relacionado.
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
RU2383547C2 (ru) 2003-08-28 2010-03-10 Чоонгвае Фарма Корпорейшн Модуляция бета-катенин/tcf-активируемой транскрипции
US20050222158A1 (en) * 2004-03-19 2005-10-06 Andres Charles J Jr Method of treating migraine headaches using calcitonin gene related peptide mimetics
US20050209256A1 (en) * 2004-03-19 2005-09-22 Andres Charles J Jr Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists
JP2008533155A (ja) * 2005-03-18 2008-08-21 インスティテュート フォー ケミカル ジェノミックス アルファへリックス模倣剤および線維症の治療に関する方法
JP5536336B2 (ja) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
US7964181B2 (en) * 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
EP2069791B1 (en) 2006-07-27 2012-01-25 University of Maryland, Baltimore Cellular receptor for antiproliferative factor
WO2008157425A2 (en) * 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
JP2009040696A (ja) * 2007-08-07 2009-02-26 Kikkoman Corp 新規アンジオテンシン変換酵素阻害ペプチド
US9605035B2 (en) 2008-01-10 2017-03-28 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8377925B2 (en) 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8008291B2 (en) 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
BRPI0911383B1 (pt) * 2008-06-06 2021-08-31 Prism Biolab Corporation Composto, composição farmacêutica, uso do referido composto, agentes para tratar ou prevenir câncer, fibrose, restenose associada com angioplastia, doença renal policística, doença de angiogênese aberrante, complexo de esclerose tuberosa (tsc) tumor associado com kshv, perda de cabelo, e doença de alzheimer, e processo para preparar o referido composto
EP2340047A1 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
EP2337585A1 (en) * 2008-09-19 2011-06-29 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
WO2010033216A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
EP2334337A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
JP5545573B2 (ja) 2008-10-14 2014-07-09 株式会社 PRISM BioLab アルファへリックスミメティック及び関連の方法
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
CA2758904C (en) * 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
DK2424885T3 (en) 2009-04-28 2016-06-06 Univ Vanderbilt Compositions and methods for the treatment of disorders involving epitelcelleapoptose
EP2427451B1 (en) 2009-05-07 2019-03-20 PRISM BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
US20120296067A1 (en) 2010-02-03 2012-11-22 Prism BioLab Co., Ltd. Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
ES2552462T3 (es) 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo
WO2012115286A1 (en) 2011-02-25 2012-08-30 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
CA2832443C (en) 2011-04-06 2020-08-25 The Board Of Regents Of The University Of Texas System Modulating bacterial mam polypeptides in pathogenic disease
US20150072933A1 (en) 2011-08-01 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Novel sequences for the control of reproduction in fish
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
WO2014164395A1 (en) 2013-03-11 2014-10-09 Dana-Farber Cancer Institute, Inc. Combination anti-estrogen receptor cancer therapy using muc1 peptides and chemotherapeutics
WO2014164394A1 (en) 2013-03-11 2014-10-09 Dana-Farber Cancer Institute, Inc. Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics
JP6471385B2 (ja) 2013-03-15 2019-02-20 グラディエーター・バイオサイエンシーズ・インコーポレイテッド 標的化剤としてのGlaドメイン
JP6507336B2 (ja) 2013-10-18 2019-05-08 株式会社 PRISM BioLab Cbp/カテニン阻害剤を用いる肝線維症の治療
WO2018035429A1 (en) 2016-08-18 2018-02-22 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
PE20201462A1 (es) 2017-09-05 2020-12-17 Gladiator Biosciences Inc Metodo de direccionamiento de exosomas
WO2022092294A1 (ja) 2020-10-30 2022-05-05 学校法人慶應義塾 サルコペニア関連疾患等の新規治療および予防
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103577A1 (en) * 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1994003494A1 (en) * 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of reverse turns and peptides containing the same
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5886186A (en) * 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof

Also Published As

Publication number Publication date
EP0876371A1 (en) 1998-11-11
JPH11513986A (ja) 1999-11-30
DE69613861T2 (de) 2001-11-15
EP0876371B1 (en) 2001-07-11
CA2235138A1 (en) 1997-05-01
ATE203025T1 (de) 2001-07-15
AU7520596A (en) 1997-05-15
WO1997015577A1 (en) 1997-05-01
DE69613861D1 (de) 2001-08-16
US5929237A (en) 1999-07-27
KR19990067102A (ko) 1999-08-16
AU719620B2 (en) 2000-05-11
CA2235138C (en) 2005-04-05

Similar Documents

Publication Publication Date Title
DE69613861D1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
CA2286733A1 (en) Reverse-turn mimetics and methods relating thereto
ATE301656T1 (de) Reverse-turnmimetika und damit zusammenhängendes verfahren
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
BRPI0409124A (pt) miméticos de direção inversa e método relacionado aos mesmos
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
DE69635653D1 (de) Peptide als vektoren zur intrazellulären adressierung von aktiven molekülen
ATE370734T1 (de) Reverse-turn mimetika als alpha 4ss integrin blocker
TR200000151T2 (tr) Yeni bileşimler.
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
BRPI0509888A (pt) miméticos de direção inversa e método relacionado aos mesmos
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
DE60227093D1 (de) Reverse-turn-mimetika und diese betreffendes verfahren
ES2150233T3 (es) Pirrolo(2,3-c)carbazol-6-onas condensadas que potencian la actividad de interferon gamma.
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
BR0312889A (pt) Polipeptìdeo t20 peguilado
NO981864L (no) Oppl°sningsmetoder
FR2764508B1 (fr) Nouveaux vecteurs liposomaux de principes actifs
NO980296L (no) Forbedrede terapeutiske midler
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
ATE242202T1 (de) Peptide
IT8948430A0 (it) Composti tripeptidici e loro uso farmaceutico come immuno-modulatori
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 876371

Country of ref document: ES